Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Harmony Gold Mining Co. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Harmony Gold Mining Co. trades at $16.47 (market cap $10.37B). The key difference: Harmony Gold Mining Co. is far larger — about 3.6× Dyne Therapeutics Inc. Common Stock's market cap, and Harmony Gold Mining Co. pays a 4.67% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Harmony Gold Mining Co. for 45 Days on average.
| DYN | HMY | |
|---|---|---|
Market Cap | $2.86B | $10.37B |
Volume | 3,341,579 | 2,951,252 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $26.04 |
52-Week Low | $14.60 | $13.32 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $2.18B | $10.42B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HMY trades at $16.29, down 2.34% today, amid bearish technical signals but strong fundamentals. The stock shows robust revenue growth from $42.6B in 2022 to $73.9B in 2025, with net income surging to $14.4B. Valuation ratios remain attractive with P/E of 5.96 and EV/EBITDA of 3.64. Recent earnings showed mixed results with two beats and two misses in the last four quarters.
The outlook is cautiously optimistic given strong profitability metrics (ROE 46.23%, net margin 29.57%) and copper expansion plans, though technical weakness and analyst skepticism (70% hold rating) suggest near-term volatility. Key risks include gold price dependency and execution challenges in diversification efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
